LDS/Medical Tests/Vitamin K Epoxide Reductase Complex, Subunit 1 (VKORC1) Genotyping

Vitamin K Epoxide Reductase Complex, Subunit 1 (VKORC1) Genotyping

The VKORC1 gene at 16p11.2 encodes for the catalytic subunit of the VKOR (Vitamin K epoxide reductase) enzyme. The VKOR enzyme is synthesized in the endoplasmic reticulum and serves for the reduction of inactive vitamin K epoxide into functionally active vitamin K. Vitamin K is an essential cofactor for the vitamin K-dependent gamma-carboxylation of coagulation factors which is required for normal blood clotting. Polymorphisms in the VKORC1 gene have been linked to bleeding disorders via defective VKOR enzyme synthesis, and failure in the gamma-carboxylation of coagulation factors.

Importantly, the VKOR enzyme is also the target of warfarin, a widely used oral anticoagulant drug. Warfarin acts by inhibiting the VKOR enzyme and ultimately suppresses gamma-carboxylation of coagulation factors. Since polymorphisms in the VKORC1 gene may alter the enzyme’s structure, inhibit warfarin binding and impair its ability to promote anticoagulation. As a result, the dose-anticoagulant effect is may be highly altered. Such patients present with warfarin resistance and require a higher dose than the INR-standardized dose to obtain the equivalent effect.

On the other hand, multiple polymorphisms have been associated with hyperactive enzyme activity and resultant warfarin sensitivity where the standard warfarin dose is too high and can lead to minor or major bleeding episodes. In contrast to those with warfarin resistance, patients with enhancing VKORC1 mutations require a lower dose of warfarin. It is estimated that 25% of the variability in warfarin dosing to achieve the desired response is due to VKORC1 gene polymorphisms. In this regard, the FDA in 2007 approved the incorporation of VKORC1 genotype information in determining the optimal warfarin doses for patients with bleeding disorders.

  • Aids in predicting the response of the patient to standard warfarin dose
  • Useful in the identification of patients at risk of warfarin sensitivity or resistance
  • Helpful for the assessment of the therapeutic dosing of warfarin used for the treatment of bleeding disorders

The presence of polymorphisms in the VORC1 gene is suggestive of an abnormal response to warfarin. Sensitivity or resistance is determined based on the specific variants present:

  • Warfarin sensitivity: G3673A (rs9923231), and C6484T (rs9934438).

Required lowered-mean dose 24-26 mg/week.

  • Warfarin resistance: G9041A (rs7294).

Required higher-mean dose 40 mg/week.

The absence of polymorphisms in the VORC1 gene however does not rule out the possibility of warfarin sensitivity or resistance since there exist other etiologies (see below in the additional testing section).

VKORC1 Genotype 1639G G/G : Low Warfarin Sensitivity

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), conventional sequencing.

Whole blood, EDTA (Lavender-top).

Stability

  • Ambient: 7 days
  • Refrigerated: 7-14 days
CYP2C9, CYP4F2, CYP2C genotyping, PT/INR.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Pharmacogenet Genomics. 2010 Oct;20(10):642-4. [PMID: 19940803]
  • Int J Clin Pharmacol Ther. 2017 Apr;55(4):304-321. [PMID: 28025970]
  • Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. [PMID: 19297219]
  • Thromb Res. 2007;120(1):1-10. [PMID: 17161452]
  • Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. [PMID: 28520347]